https://www.degruyter.com/view/j/hmbci.2017.30.issue-3/hmbci-2017-0015/hmbci-2017-0015.xml
Summary
Prior to this, there were concerns regarding hepatic inhibition of 5AR1 leading to hepatic lipid accumulation. This new study justified my concerns about dutasteride and made me realize that it is not a safe medication. What do dutasteride users think about this?
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701851/
Summary
This study suggests that long-term dutasteride therapy is associated with increased blood glucose, HbA1c, LDL-cholesterole and TC, potentially leading to increased onset of IR and NAFLD. In addition, dutasteride increased liver transaminase activity and AMS score suggesting increased inflammation and reduced quality of life. Dutasteride therapy also worsened ED and resulted in reduction in T levels. These findings raise serious safety concerns regarding metabolic dysfunction and adverse sexual side effects of long-term dutasteride therapy. Clinicians are strongly urged to discuss these potential health adverse effects of dutasteride treatment with their patients prior to instituting this form of therapy.
Prior to this, there were concerns regarding hepatic inhibition of 5AR1 leading to hepatic lipid accumulation. This new study justified my concerns about dutasteride and made me realize that it is not a safe medication. What do dutasteride users think about this?
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701851/